Belumosudil for early treatment of chronic graft-versus-host disease
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have at least one symptom of chronic graft-versus-host disease (cGVHD), like skin changes, mouth sores, or eye dryness, and a doctor has diagnosed it.
- If only your eyes are affected, an eye doctor must confirm the cGVHD diagnosis.
- You cannot have started any new immune-suppressing medication in the 2 weeks before joining the trial.
- You must be 18 years or older.
- You must be able to take pills by mouth.
- Your kidneys and liver must be working well enough (based on simple blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called belumosudil for children with chronic graft-versus-host disease (GVHD) that hasn't improved with at least 2 other treatments. The goal is to see if it can help control the disease and improve symptoms.
This study tests an oral medication called belumosudil for people who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It aims to see how safe the drug is. You may qualify if you have already tried at least two other treatments and are currently on a stable steroid dose.
This study tests a new medicine called belumosudil for people who have chronic graft-versus-host disease (cGVHD) that has not improved with at least two earlier treatments. It compares belumosudil to other available treatments to see which works better and is safer.
This trial tests whether crushing belumosudil tablets changes how the drug works in people with chronic graft-versus-host-disease (GVHD), a complication after a stem cell transplant. It helps doctors know if taking crushed pills is as effective as whole tablets.
This study compares how the body absorbs a drug called belumosudil when given as a liquid versus a tablet. It aims to see if the two forms are similar, which could help decide the best way to give the drug in the future.
This study tests a new drug called axatilimab for people with a specific type of chronic graft-versus-host disease (cGVHD) that causes hardening or thickening of the skin or joints. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack your body. The study aims to see if axatilimab can improve these sclerotic symptoms. If you have this condition and it was recently diagnosed (within the last year), you might qualify to participate.
Hear when a new Chronic Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.